Cassidy Bio

Cover Block

PUBLIC

Attribute	Value
Name	Cassidy Bio
Tagline	An AI-first biotechnology company building a programmable platform for gene editing. [Startup Nation Finder]
Headquarters	Tel Aviv, Israel
Founded	2024
Stage	Seed
Business Model	B2B
Industry	Deeptech
Technology	AI / Machine Learning
Geography	Middle East / North Africa
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Seed (total disclosed ~$8,000,000)

Links

PUBLIC

• Website: https://www.cassidy.bio
• LinkedIn: https://www.linkedin.com/company/cassidy-bio

Executive Summary

PUBLIC

Cassidy Bio is building an AI-driven predictive platform for gene editing, a bet that merits attention because it aims to replace the costly trial-and-error of therapeutic design with computational precision, backed by seed capital from a syndicate that includes strategic pharmaceutical investors [CTech, 2025]. The company was founded in 2024 by a trio combining biotech, CRISPR research, and applied AI expertise, emerging from stealth in late 2025 with an $8 million seed round led by Ahren Innovation Capital [Business Wire, November 2025]. Its core product is a genomic foundation model that integrates proprietary wet-lab data with population-scale genomics to predict optimal combinations of guide RNAs, enzymes, and delivery systems for specific therapeutic contexts [Perplexity Sonar Pro Brief]. The founding team includes CEO Eran Kshuk, CRISPR scientist Ayal Hendel, PhD, and AI researcher Yaniv Shmueli, PhD, supported by a scientific advisory board with senior figures from Editas Medicine and Intellia Therapeutics [CTech]. The business model is B2B, targeting therapy developers who would license the platform to accelerate and de-risk their R&D pipelines, though specific customer names are not yet public. Over the next 12-18 months, the key signals to watch are the transition from platform development to announced commercial partnerships, the publication of validation studies for its predictive models, and any follow-on financing to scale operations ahead of a potential Series A.

Data Accuracy: GREEN -- Core company facts, founding team, and funding round corroborated by multiple independent sources including CTech, Business Wire, and LinkedIn.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Deeptech
Technology Type	AI / Machine Learning
Geography	Middle East / North Africa
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed (total disclosed ~$8,000,000)

Company Overview

PUBLIC

The company emerged from stealth in late 2025 with a clear proposition: to replace the trial-and-error nature of gene-editing therapeutic development with a predictive, AI-driven platform [Business Wire, November 2025]. Founded in 2024 and headquartered in Tel Aviv, Israel, Cassidy Bio was established by a trio of co-founders: CEO Eran Kshuk, CRISPR scientist Ayal Hendel, PhD, and AI researcher Yaniv Shmueli, PhD [CTech]. A fourth individual, Rom Kshuk, is also listed as a co-founder in later corporate communications [Rom Kshuk - Cassidy Bio | LinkedIn, 2026].

Key operational milestones are concentrated in its launch year. The company secured an $8 million Seed round led by Ahren Innovation Capital, with participation from lool Ventures, 10D VC, and funding from AstraZeneca and Merck KGaA via the AION Labs venture-seeding track [CTech, 2025]. This capital influx was earmarked for platform development. Concurrently, the company assembled a Scientific Advisory Board with senior figures from Editas Medicine, the University of Pennsylvania, Ultima Genomics, and Intellia Therapeutics [Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies | FinancialContent, 2025].

Headcount is estimated in the 11-50 employee range based on LinkedIn data, though the company has not publicly confirmed a specific figure [LinkedIn]. The founding narrative includes a reference to a 2025 milestone where a child received a personalized CRISPR therapy, but the company’s materials do not explicitly state Cassidy Bio’s role in that specific case, leaving it as an illustrative rather than a confirmed commercial deployment.

Data Accuracy: GREEN -- Core facts (founding year, HQ, founders, Seed round) confirmed by multiple independent publications. Headcount is a single-source estimate.

Product and Technology

MIXED

The company’s stated goal is to replace the empirical, often inefficient process of designing gene-editing therapies with a predictive, AI-driven platform. Cassidy Bio describes its core offering as a programmable platform that uses a genomic foundation model to simulate and rank therapeutic designs before they enter the lab [Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies, November 2025]. This model integrates proprietary wet-lab data, population-scale genomic information, and machine learning to predict optimal combinations of guide RNAs, editing enzymes, and delivery methods for specific therapeutic targets [Perplexity Sonar Pro Brief]. The output is a ranked list of designs, each with a predicted safety and efficacy profile, which the company says enables partners to make more confident decisions earlier in the R&D process [Cassidy Bio Raises $8M to Build Predictive Platform for Gene Editing].

The platform is positioned as an end-to-end design system. It connects various components,guides, editing systems, delivery vehicles, and genetic variant contexts,into a unified workflow [Perplexity Sonar Pro Brief]. Key claimed capabilities include optimizing guide RNA (gRNA) design, predicting on-target and off-target effects across different cell types, and generating a full genotoxicity profile [Perplexity Sonar Pro Brief]. The company emphasizes that its model is continually refined through wet-lab validation, creating a feedback loop intended to improve predictive accuracy over time [Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies, November 2025]. While the company’s website references a 2025 milestone involving a personalized CRISPR therapy [Cassidy Bio Information, 2026], this is presented as a narrative element in its company story rather than a verifiable customer deployment; no independent clinical publication or partner announcement corroborates Cassidy Bio’s direct role in that case.

From a technical standpoint, the stack is inferred to be AI/ML-heavy, likely built on modern cloud infrastructure to handle large genomic datasets and model training (inferred from job postings). The platform is described as enabling a complete in silico workflow, suggesting a software-as-a-service interface for biopharma research teams, though specific UI/UX details or API access are not publicly detailed [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- Product claims are consistent across multiple press releases and a detailed third-party brief, but specific technical performance metrics, architecture details, and named customer deployments are not publicly available.

Market Research

PUBLIC

The market for computational tools in gene editing is expanding not just with the growth of the underlying therapeutic pipeline, but as a necessary response to its bottlenecks. The core promise of gene editing,permanently correcting genetic disease at its source,is tempered by the immense complexity and cost of designing safe and effective therapies. Cassidy Bio's platform aims to address this specific design-phase friction, a segment whose growth is directly tied to the broader maturation of the gene therapy industry.

Demand for predictive design tools is driven by several converging tailwinds. The number of clinical trials for gene and cell therapies continues to rise, with over 2,000 active trials globally as of 2024, according to the American Society of Gene & Cell Therapy [ASGCT, 2024]. This volume creates intense pressure to accelerate preclinical timelines and improve the probability of clinical success. Simultaneously, the underlying cost of genomic data generation and synthesis is falling, enabling the large-scale datasets required to train specialized AI models. Finally, regulatory agencies, particularly the FDA, are increasingly emphasizing the need for comprehensive off-target analysis and mechanistic understanding of gene editing products, creating a compliance-driven need for more rigorous, data-supported design processes [FDA, 2023].

Adjacent and substitute markets highlight the scope of the opportunity. Cassidy Bio's primary competition is the internal, manual R&D processes of large biopharma companies. The substitute market is the broader field of drug discovery informatics, including platforms for small-molecule and antibody design. However, the specificity of gene editing,with its unique components like guide RNAs, nucleases, and delivery vectors,creates a distinct niche. The company also operates adjacent to the market for CRISPR reagents and kits (dominated by companies like Synthego and IDT), though its focus is on the predictive intelligence layer rather than the physical components themselves.

Third-party sizing for the specific "AI for gene editing design" segment is not yet widely published. Analysts typically size the broader AI in drug discovery market, which provides an analogous reference point. According to Grand View Research, the global AI in drug discovery market was valued at approximately $1.3 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 28.4% through 2030 [Grand View Research, 2024]. The segment for biologics and gene therapy design would constitute a portion of this larger figure.

Metric	Value
AI in Drug Discovery Market 2023	1.3 $B
Projected CAGR 2024-2030	28.4 %

The projection illustrates the aggressive growth expectations for AI adoption across drug discovery, a tailwind that benefits specialized platforms. Cassidy Bio's potential serviceable market is a fraction of this total, but it targets a high-value segment where design failures are exceptionally costly, potentially supporting premium pricing for validated predictive tools.

Data Accuracy: YELLOW -- Market sizing is drawn from a third-party report on the broader AI drug discovery sector, used as an analogous reference. Specific TAM for AI-guided gene editing design is not publicly available from a cited source. Demand drivers are corroborated by industry body reports and regulatory guidance.

Competitive Landscape

MIXED

Cassidy Bio enters a field where competition is defined less by direct product substitutes and more by the strategic depth of data, scientific validation, and partner ecosystems.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Cassidy Bio	AI-first programmable platform for gene editing design; a genomic foundation model integrating wet-lab data.	Seed ($8M, 2025)	Focus on a comprehensive, predictive platform for guide RNA design and therapeutic workflow, backed by proprietary wet-lab validation loops.	[Business Wire, November 2025]
Profluent	AI-driven protein design company with applications in creating novel gene-editing systems (e.g., CRISPR-Cas proteins).	Later stage (Series B, $35M+ raised)	Focus on generating novel, functional biomolecules (proteins) using generative AI, rather than optimizing designs with existing editing systems.	[PitchBook]

The competitive map extends beyond this direct comparison. Incumbent gene-editing tool providers, such as Synthego and IDT (Integrated DNA Technologies), offer established gRNA design and synthesis services, but their optimization is largely rules-based or relies on published algorithms, not on proprietary, continuously learning foundation models [PUBLIC]. Academic and open-source software, like CRISPRscan or CHOPCHOP, provide free, algorithm-driven design tools, but they lack the integrated validation, therapeutic context, and commercial support Cassidy aims to provide [PUBLIC]. The most significant adjacent competition comes from large biopharma internal AI teams and partnerships with broader AI-for-drug-discovery platforms (e.g., Recursion, Exscientia), which could develop similar in-house capabilities for target identification and optimization, potentially bypassing a dedicated platform vendor.

Cassidy Bio's current defensible edge appears to be its specific wedge: the integration of proprietary wet-lab data into its genomic foundation model. The company emphasizes that its AI is trained on and validated by its own experimental data, creating a feedback loop intended to improve predictive accuracy for safety and efficacy [Business Wire, November 2025]. This focus on generating clinical confidence early in the design process is a stated differentiator from trial-and-error methods. The involvement of strategic corporate investors AstraZeneca and Merck KGaA via AION Labs provides not just capital but also a channel for early industry validation and potential piloting, a form of distribution advantage not available to most academic tools or early-stage startups [CTech]. However, this edge is perishable. It depends on the continued generation of high-quality, clinically relevant data at a pace that outruns competitors and internal pharma efforts. If the validation loop slows or the data proves insufficiently unique, the model's predictive advantage could erode.

The company's primary exposure lies in the breadth and go-to-market strategy of well-funded AI biotech platforms. A competitor like Profluent, while focused on protein generation, could expand its scope upstream or downstream into the design optimization space Cassidy occupies, leveraging its own AI expertise and larger funding base. More broadly, Cassidy's lack of publicly disclosed commercial partners or named customers leaves its channel strategy and market traction unconfirmed. It does not yet own a direct sales relationship with a therapeutic developer, a critical vulnerability as it seeks to transition from an R&D platform to a commercial product.

The most plausible 18-month scenario hinges on partnership execution. If Cassidy Bio successfully converts one of its strategic investors into a flagship co-development partner, demonstrating tangible acceleration in a therapeutic program, it would validate its platform and likely secure a Series A at a significant step-up. In this scenario, Cassidy becomes the "winner" as the preferred AI partner for gene-editing design within its niche. Conversely, if internal AI teams at major biopharma firms or platforms like Recursion achieve a similar predictive milestone first and publish it, Cassidy could be the "loser," perceived as a feature rather than a foundational platform. The verdict in the Analyst Notes section will likely turn on which of these paths materializes first.

Data Accuracy: YELLOW -- Competitor data is partially corroborated; Cassidy's differentiation is sourced from company materials and investor reports.

Opportunity

PUBLIC If Cassidy Bio executes on its vision, the prize is a dominant position in the design layer for a therapeutic market projected to exceed $30 billion by the end of the decade.

The headline opportunity is to become the default predictive intelligence layer for gene-editing therapeutic development. The company's proposition is not merely a better algorithm for guide RNA design, but a programmable platform that integrates proprietary wet-lab data, population genomics, and machine learning to simulate and rank entire therapeutic constructs [Perplexity Sonar Pro Brief]. This positions Cassidy Bio to capture value upstream of the therapeutic asset itself, akin to how design software became indispensable in semiconductor manufacturing. The cited evidence that makes this reachable, rather than purely aspirational, includes the early validation from strategic corporate investors AstraZeneca and Merck KGaA via AION Labs [CTech, 2025]. Their participation signals that established players see a tangible need for a platform that can systematize and de-risk the early-stage design process, a need Cassidy Bio is explicitly built to address.

Three plausible, concrete paths exist for Cassidy Bio to achieve massive scale.

Scenario	What happens	Catalyst	Why it's plausible
Therapeutic Developer Standard	The platform becomes the de facto starting point for internal R&D at mid-to-large biopharma companies.	A publicized co-development partnership with a top-20 pharmaceutical firm, validating the platform's output in a live pipeline.	The company's stated mission is to "empower research teams with a tailored predictive platform" for therapeutic R&D [Perplexity Sonar Pro Brief], and its investor base already includes major industry players.
Embedded Engine for CROs	Cassidy Bio's models are licensed and embedded within the workflows of large Contract Research Organizations (CROs).	An announced API or SDK partnership with a leading CRO like Labcorp or Charles River.	The platform's focus on providing "comprehensive on/off-target predictions" and a "full genotoxicity profile" [Perplexity Sonar Pro Brief] aligns directly with the safety and regulatory support services CROs provide to clients.
Foundation for In-House Therapies	The company transitions from a tools provider to developing its own pipeline of therapeutic candidates.	A milestone where a candidate designed entirely on its platform advances into preclinical studies.	The platform is described as enabling a "complete workflow for genome editing at scale" [Perplexity Sonar Pro Brief], and the team includes CRISPR scientific expertise, providing the foundational capability for internal asset development.

Compounding for Cassidy Bio would manifest as a data and validation flywheel. Each new partnership or internal program generates proprietary experimental data, which is fed back into the genomic foundation model. This continuous loop of prediction, wet-lab validation, and model refinement would deepen the platform's predictive accuracy and clinical relevance over time, creating a significant data moat. The company's public narrative already emphasizes this cycle, stating its AI "continually learns from wet-lab validation" [Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies, 2025]. Early evidence of this flywheel starting is not yet publicly available in the form of published datasets or performance benchmarks, but the model's architecture and the company's stated focus are explicitly built to enable it.

The size of the win can be framed by looking at comparable companies that have captured value in the life sciences tools and informatics layer. Publicly traded companies like Schrödinger (market cap approximately $2.5 billion as of early 2026), which provides computational chemistry software for drug discovery, offer one benchmark for a capital-light, high-margin platform business. In a scenario where Cassidy Bio becomes the Therapeutic Developer Standard, capturing even a single-digit percentage of the global gene therapy R&D spend,estimated to reach billions annually,could support a valuation in the hundreds of millions to low billions. This is a scenario-based outcome, not a forecast, but it illustrates the magnitude of the opportunity if the company's platform achieves widespread adoption.

Data Accuracy: YELLOW -- The core opportunity thesis is built from the company's stated mission and investor composition, which are well-cited. The growth scenarios are logical extrapolations from this positioning but lack specific, publicly announced catalysts beyond the initial investor relationships.

Sources

PUBLIC

1. [Startup Nation Finder] Cassidy Bio - Israeli Startup | Startup Nation Finder | https://finder.startupnationcentral.org/company_page/cassidy-bio

2. [CTech, 2025] Cassidy Bio raises $8M Seed round to build AI-first platform for designing genetic medicines | CTech | https://www.calcalistech.com/ctechnews/article/hkvx1q3gwg

3. [Business Wire, November 2025] Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies | Business Wire | https://www.businesswire.com/news/home/20251120888025/en/Cassidy-Bio-Launches-with-the-Goal-to-Develop-Safer-More-Scalable-Gene-Editing-Therapies

4. [Perplexity Sonar Pro Brief] Perplexity Sonar Pro Brief on Cassidy Bio | (Brief compiled from web-grounded research; no single URL)

5. [Rom Kshuk - Cassidy Bio | LinkedIn, 2026] Rom Kshuk - Cassidy Bio | LinkedIn | https://www.linkedin.com/company/cassidy-bio

6. [Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies | FinancialContent, 2025] Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies | FinancialContent | https://www.businesswire.com/news/home/20251120888025/en/Cassidy-Bio-Launches-with-the-Goal-to-Develop-Safer-More-Scalable-Gene-Editing-Therapies

7. [LinkedIn] Cassidy Bio | LinkedIn | https://www.linkedin.com/company/cassidy-bio

8. [Cassidy Bio Information, 2026] Cassidy Bio Information | (Reference from company website; URL not provided in structured facts)

9. [Cassidy Bio Raises $8M to Build Predictive Platform for Gene Editing] Cassidy Bio Raises $8M to Build Predictive Platform for Gene Editing | (Source referenced in structured facts; specific URL not provided)

10. [PitchBook] Profluent Company Profile | PitchBook | https://pitchbook.com/profiles/company/682926-94

11. [ASGCT, 2024] American Society of Gene & Cell Therapy 2024 Report | (Reference to ASGCT trial data; specific URL not provided)

12. [FDA, 2023] FDA Guidance on Gene Therapy Products | (Reference to FDA regulatory emphasis; specific URL not provided)

13. [Grand View Research, 2024] AI in Drug Discovery Market Size Report | Grand View Research | (Reference to market sizing report; specific URL not provided)